Ex­clu­sive: As­traZeneca and Vaxess de­vel­op­ing skin patch mR­NA vac­cines for pan­dem­ic flu

As­traZeneca is de­vel­op­ing a nov­el type of mR­NA vac­cine that can be ad­min­is­tered as a shelf-sta­ble skin patch in­stead of a shot, po­ten­tial­ly mak­ing dis­tri­b­u­tion and ad­min­is­tra­tion of pan­dem­ic vac­cines eas­i­er, End­points News has learned.

The phar­ma­ceu­ti­cal gi­ant is part­ner­ing with Boston biotech start­up Vaxess, which could get up to $10.3 mil­lion from As­traZeneca in a joint ef­fort to de­vel­op pro­to­type vac­cines for pan­dem­ic in­fluen­za, Vaxess told End­points in an ex­clu­sive in­ter­view. Those funds are part of a larg­er award worth up to $80 mil­lion from the De­part­ment of De­fense that As­traZeneca could use to de­vel­op and test the vac­cine through a Phase I/II clin­i­cal study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER